Daily Stock Analysis, AERI, Aerie Pharmaceuticals Inc, priceseries

Aerie Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
14.26
Close
13.95
High
14.26
Low
13.27
Previous Close
13.97
Daily Price Gain
-0.02
YTD High
26.26
YTD High Date
Jan 9, 2020
YTD Low
10.80
YTD Low Date
Mar 23, 2020
YTD Price Change
-9.85
YTD Gain
-41.39%
52 Week High
26.34
52 Week High Date
Jul 15, 2019
52 Week Low
10.80
52 Week Low Date
Mar 23, 2020
52 Week Price Change
-11.55
52 Week Gain
-45.29%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Oct 10. 2017
55.35
Oct 26. 2017
61.69
12 Trading Days
11.45%
Link
LONG
May 31. 2018
51.30
Jul 2. 2018
65.55
22 Trading Days
27.79%
Link
LONG
Jan 9. 2019
39.84
Feb 6. 2019
45.18
19 Trading Days
13.39%
Link
LONG
Dec 3. 2019
19.08
Dec 30. 2019
23.00
18 Trading Days
20.53%
Link
LONG
Apr 8. 2020
13.40
Apr 21. 2020
14.08
8 Trading Days
5.04%
Link
Company Information
Stock Symbol
AERI
Exchange
NasdaqGM
Company URL
http://www.aeriepharma.com
Company Phone
919-313-9650
CEO
Vicente J. Anido
Headquarters
North Carolina
Business Address
7020 KIT CREEK ROAD, SUITE 270, RESEARCH TRIANGLE PARK, NC 27709
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Major
CIK
0001337553
About

Aerie Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which is focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. It product candidates are Rhopressa and Roclatan. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem and Eric J. Toone on June 22, 2005 and is headquartered in Irvine, CA.

Description

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The company is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. was founded in 2005 and is based in Irvine, California.